US EditionHarbour BioMed Appoints Yajie Li as Chief Medical Officer
- Harbour BioMed announced the appointment of Yajie Li as Chief Medical Officer .
- Yajie Li will lead clinical development, regulatory strategy, and medical affairs for Harbour BioMed's clinical-stage programs.
- Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, expressed satisfaction with the appointment, noting Li's expertise.
- Yajie Li holds a master's degree in Rheumatology and Immunology from Peking Union Medical College.
64 Articles
64 Articles
Chatham Star Tribune
Harbour BioMed Appoints Yajie Li as Chief Medical Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of…
Harbour BioMed taps Li to steer late-stage trials
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Execu…
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
